Gertz S D, Kalan J M, Kragel A H, Roberts W C, Braunwald E
Pathology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
Am J Cardiol. 1990 Apr 15;65(15):953-61. doi: 10.1016/0002-9149(90)90996-e.
The hearts of 52 patients (aged 61 +/- 11 years, 34 men) who participated in the Thrombolysis in Myocardial Infarction (TIMI) Study and died from 5 hours to 260 days (median 2.7 days) after onset of chest pain were studied. One heart became available at cardiac transplantation. Of the 52 patients, 38 received recombinant tissue plasminogen activator (rt-PA) not followed by percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG). Eight had PTCA, and 6 had CABG. The infarcts were hemorrhagic by gross inspection (with histologic confirmation) in 23 patients, nonhemorrhagic in 20, not visible grossly in 2 and, in 7, there was no myocardial necrosis by either gross or histologic examination.(ABSTRACT TRUNCATED AT 250 WORDS)
对52例参与心肌梗死溶栓（TIMI）研究的患者（年龄61±11岁，34例男性）的心脏进行了研究，这些患者在胸痛发作后5小时至260天（中位数2.7天）死亡。有1颗心脏可用于心脏移植。52例患者中，38例接受了重组组织型纤溶酶原激活剂（rt-PA）治疗，随后未进行经皮腔内冠状动脉成形术（PTCA）或冠状动脉旁路移植术（CABG）。8例接受了PTCA，6例接受了CABG。通过大体检查（经组织学证实），23例患者的梗死灶为出血性，20例为非出血性，2例大体不可见，7例经大体或组织学检查均无心肌坏死。（摘要截取自250字）
